NHP — National Healthcare Properties — reported its Q1 2026 results after the close on May 13, a day ahead of its scheduled May 14 event. Funds from operations came in at $0.26 per share, doubling the year-ago figure of $0.13, while revenue dipped marginally to $86.3M from $86.4M.
The most striking data trail heading into this print was in the borrow market — not the short interest ledger. Cost to borrow has collapsed from a peak above 27% in late April to just over 5% today, a drop of more than 50% in a single week. That tells a clear story: short sellers who rushed to build positions around the late-April period found borrow extremely scarce and expensive, then began unwinding or rolling as conditions eased. Short interest itself is modest, running at roughly 1.5 million shares on two days of exchange-reported volume — well below the threshold where short positioning becomes a primary narrative driver.
Availability has loosened alongside the CTB decline. Borrow utilization peaked at 40.9% — the highest level of the past year — on April 28, before easing back to around 22% by May 12. That late-April squeeze coincided with cost-to-borrow touching 27.5%, the highest reading in the available history. The normalization since then suggests much of the urgency has dissipated. With a short score of 40 and a days-to-cover of less than one day, the short book here is not a crowded trade.
On the institutional side, Millennium Management entered as a new holder with nearly 1.9 million shares as of late April — a meaningful position relative to total float for a micro-cap REIT trading at $13.16. Several board-linked insiders also added shares over the same period, though volumes were small. The only executive trade in the available record is a President/CEO sale from September 2025, which is too dated to carry forward-looking weight. No analyst coverage or consensus data is available for this stock, leaving the Q1 FFO beat and the 8-K filed May 8 — disclosing entry into a material definitive agreement — as the key catalysts the market will now weigh against a stock down 1.7% on its last close.
The earnings report is therefore less about whether NHP can sustain its FFO recovery and more about whether the May 8 agreement and the doubling of per-share FFO are enough to justify a re-rating in a thinly covered, small-cap healthcare REIT where institutional participation is just starting to build.
See the live data behind this article on ORTEX.
Open NHP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
